Warren J W, Benmaman J D, Wannamaker B B, Levy R H
Clin Pharmacol Ther. 1980 Nov;28(5):646-51. doi: 10.1038/clpt.1980.216.
Carbamazepine and ethosuximide are used together to treat epileptic mixed-seizure patterns. Since carbamazepine has been shown to induce drug-metabolizing enzyme(s) in the liver, it follows that carbamazepine may alter ethosuximide disposition. Six normal subjects took one 250-mg ethosuximide capsule twice each day for 55 consecutive doses (study days 1 to 28) and one 200-mg carbamazepine tablet each evening from study days 11 to 27. Plasma samples were collected on study days 10, 17, 21, and 28. Mean steady-state concentrations of ethosuximide declined by 17% from a preinduction (study day 10) level of 32.2 +/- 5.6 micrograms/ml to a postinduction level of 26.8 +/- 5.2 micrograms/ml on study day 28. Ethosuximide clearance increased (alpha = 0.05) between study days 10 and 28 from 0.664 +/- 0.120 to 0.800 +/- 0.0154 l/hr. The time course of induction was analyzed using a kinetic induction theory. Ethosuximide half-life was lowered from mean - 53.7 +/- 11.5 hr (before induction) to mean = 44.6 +/- 10.7 hr (after induction); the difference between some subjects was large. These data show that ethosuximide disposition is altered by carbamazepine.
卡马西平和乙琥胺联合用于治疗癫痫混合发作类型。由于已证明卡马西平可诱导肝脏中的药物代谢酶,因此卡马西平可能会改变乙琥胺的处置。六名正常受试者连续55剂(研究第1天至28天)每天服用两次250毫克乙琥胺胶囊,从研究第11天至27天每晚服用一片200毫克卡马西平片。在研究第10、17、21和28天采集血浆样本。乙琥胺的平均稳态浓度从诱导前(研究第10天)的32.2±5.6微克/毫升水平下降17%,至研究第28天的诱导后水平26.8±5.2微克/毫升。乙琥胺清除率在研究第10天至28天之间增加(α = 0.05),从0.664±0.120升/小时增至0.800±0.0154升/小时。使用动力学诱导理论分析诱导的时间过程。乙琥胺半衰期从平均53.7±11.5小时(诱导前)降至平均44.6±10.7小时(诱导后);一些受试者之间的差异很大。这些数据表明乙琥胺的处置被卡马西平改变。